Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive

Vaxcyte announced that its 31-valent pneumococcal conjugate vaccine candidate, VAX-31, met all prespecified primary endpoints in the OPUS-1 pivotal adult Phase 3 trial, demonstrating noninferiority and superiority compared to Prevnar 20 and Capvaxive. The vaccine showed a strong safety profile and was well tolerated across all age groups studied. Vaxcyte plans to report results from additional Phase 3 trials (OPUS-2 and OPUS-3) in the first half of 2027, with a biologics license application submission expected in the first half of 2028.